Holen Sie sich die Stockscreener-App
7.91
3.77%
-0.31
Vorhandelsmarkt:
8.19
0.28
+3.54%
Schlusskurs vom Vortag:
$8.22
Offen:
$9.16
24-Stunden-Volumen:
1.88M
Relative Volume:
3.44
Marktkapitalisierung:
$458.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-4.2074
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
-13.65%
1M Leistung:
-5.95%
6M Leistung:
+107.07%
1J Leistung:
+147.96%
1-Tages-Spanne:
$7.715
$9.16
1-Wochen-Bereich:
$7.715
$9.285
52-Wochen-Spanne:
$2.612
$13.60
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Vergleichen Sie OMER mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
7.91 | 458.38M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
4,671 Shares in Omeros Co. (NASDAQ:OMER) Acquired by Quantbot Technologies LP - Defense World
Omeros (NASDAQ:OMER) Receives “Buy” Rating from D. Boral Capital - Defense World
Omeros (NASDAQ:OMER) Receives “Hold” Rating from Needham & Company LLC - Defense World
Omeros Corporation’s Earnings Call Highlights Progress and Challenges - TipRanks
Omeros Corporation (NASDAQ:OMER) Q4 2024 Earnings Call Transcript - Insider Monkey
Omeros: Q4 Earnings Snapshot - CT Insider
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo
Omeros Corporation Reports 2024 Financial Results - TipRanks
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs - Investing.com Canada
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% - Investing.com
OMEROS CORP SEC 10-K Report - TradingView
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Omeros (OMER) to Release Quarterly Earnings on Monday - Defense World
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
In the Green: Omeros Corporation (OMER) Closes at 8.52, Up/Down -6.99 from Previous Day - DWinneX
Omeros Corporation (OMER) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Trend Tracker for (OMER) - news.stocktradersdaily.com
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements - TipRanks
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Joplin Globe
Charles Schwab Investment Management Inc. Decreases Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Bank of New York Mellon Corp Sells 4,919 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros to activate site for Phase III programme of zaltenibart for PNH - Yahoo Finance
D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros (OMER) Expected to Announce Earnings on Monday - Defense World
Omeros advances Phase 3 trials for PNH treatment zaltenibart - Investing.com
Omeros Says Trial Site Activation Underway for Phase 3 Study of Zaltenibart -March 21, 2025 at 12:53 pm EDT - MarketScreener
Omeros advances Phase 3 trials for PNH treatment zaltenibart By Investing.com - Investing.com South Africa
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - The Joplin Globe
Omeros' New PNH Drug Could Transform Treatment: 8-Week Dosing vs Current 2-Week Standard - Stock Titan
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
US Bancorp DE Takes $81,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
(OMER) On The My Stocks Page - Stock Traders Daily
Omeros Corporation Receives Commitment Of Over $4 Million From Nida For Further Development Of The Company'S Oms527 Program To Treat Cocaine Use Disorder - Marketscreener.com
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder - Yahoo Finance
Major Breakthrough: First-Ever Cocaine Addiction Drug Receives $4M NIDA Funding - Stock Titan
Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com - Defense World
Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com - Defense World
New York State Common Retirement Fund Increases Stake in Omeros Co. (NASDAQ:OMER) - Defense World
The time has not yet come to remove your chips from the table: Omeros Corporation (OMER) - SETE News
Investor Network: Omeros Corporation to Host Earnings Call - ACCESS Newswire
Blue Trust Inc. Sells 1,910 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Loss-Making Omeros Corporation (NASDAQ:OMER) Expected To Breakeven In The Medium-Term - Simply Wall St
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us (OMER) - Seeking Alpha
Trading (OMER) With Integrated Risk Controls - Stock Traders Daily
Omeros Corporation Announces Statistical Analysis Results for Expanded Access ProgramSeattle, Washington–(BUSINESS WIRE)–Feb 20, 2025–Omeros Corporation (NASDAQ: OMER) announced today the statistical analysis results related to the expande - Defense World
Omeros announces results for narsoplimab expanded access program - Yahoo Finance
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA - Business Wire
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):